You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Factors associated with severe adverse events in women initiating NVP-based antiretroviral therapy.

From: Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire

  All severe adverse events (N = 88)† Severe hepatotoxicity(N = 10) ZDV-related severe averse events (N = 71)
  HR 95% CI p HR 95% CI p HR 95% CI p
Age (years)          
   ≥30 (n = 137) 1.03 0.67-1.59 0.90 1.37 0.37-5.06 0.64 0.92 0.57-1.49 0.74
   <30 (n = 153) 1.00 - - 1.00 - - 1.00 - -
Body mass index (Kg/m 2 )          
   <18 (n = 40) 1.08 0.53-2.20 0.05     1.12 0.52-2.42 0.78
   ≥18 (n = 160) 1.00 - -     1.00 - -
CD4+ count/mm 3          
   >250 (n = 88) 0.68 0.41-1.12 0.14 1.75 0.48-6.39 0.40 0.64 0.36-1.14 0.13
   ≤250 (n = 202) 1.00 - - 1.00 - - 1.00 - -
WHO staging          
   Stage 3 or 4 (n = 130) 1.00 0.63-1.58 0.99 1.31 0.36-4.74 0.68 1.07 0.65-1.79 0.77
   Stage 1 or 2 (n = 160) 1.00 - - 1.00 - - 1.00 - -
ALT (IU/L)          
   ≥31(n = 50) 1.58 0.89-2.78 0.12 7.09 1.59-31.62 0.01 1.10 0.57-2.15 0.78
   <31(n = 240) 1.00 - - 1.00 - - 1.00 - -
Neutrophil level (/mm 3 )          
   <1500 (n = 28) 1.51 0.76-2.98 0.24     2.20 1.09-4.43 0.03
   ≥1500 (n = 262) 1.00 - -     1.00 - -
Hemoglobin level (g/dL)          
   ≤9.8 (n = 150) 1.15 0.73-1.82 0.56 0.66 0.16-2.79 0.57 1.35 0.81-2.23 0.25
   >9.8 (n = 140) 1.00 - - 1.00 - - 1.00 - -
Status of pregnancy          
   Pregnant (n = 125) 0.98 0.60-1.64 0.98 1.22 0.22-6.62 0.82 1.11 0.65-1.91 0.70
   Non pregnant (n = 165) 1.00 - - 1.00 - - 1.00 - -
  1. Multivariable Cox regression analyses. MTCT-Plus program, Abidjan, Côte d'Ivoire (2003-2006).
  2. HAART: Highly active antiretroviral therapy; WHO: World Health Organization; IQR: interquartile range; NVP: nevirapine; ALT: alanine aminotransferase; OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval, † If a woman had multiple severe adverse event